Genentech's Xolair more effective with fewer side effects than oral immunotherapy for food allergies

From Nasdaq: 2025-03-02 20:31:58

Genentech shared positive data from the OUtMATCH study, showing Xolair’s effectiveness in treating food allergies compared to oral immunotherapy. In a head-to-head trial, 36% of patients on Xolair could tolerate 2,000 mg of peanut protein and other allergens, versus 19% on OIT. Stage 3 of the study explores reintroducing allergenic foods post-Xolair treatment. Notably, OIT had higher adverse events, leading to discontinuation. FDA approved Xolair for food allergy treatment. Patients in Stage 3 had varying success reintroducing allergenic foods due to factors like taste and aversion. Study continues to analyze data from more patients.



Read more at Nasdaq: Genentech: Phase III Study Shows Xolair More Effective, Fewer Side Effects For Food Allergies